EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Dissecting the Spectrum of Rare BRAF Mutations in Melanoma: A Nation‐Wide Study by the Italian Melanoma Intergroup ( IMI )

Bruna Dalmasso, Maria Chiara Scaini, Laura Cendron iD, Monica Rodolfo, Ilaria Mattavelli iD, Elena Tamborini, Francesca Collina, Gerardo Ferrara, Gabriele Madonna, Carlo Cota, Elisa Melucci, Stefania Tommasi und 26 weitere

Pigment Cell & Melanoma Research · 2026-05 · 39 (3)

DOI: 10.1111/pcmr.70087 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Pigment Cell & Melanoma Research, online erschienen am 19.04.2026. Verfasst von Bruna Dalmasso und 37 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Genetics, IRCCS Azienda Ospedaliera Metropolitana, Ospedale Policlinico San Martino, Genoa, Italy. Hauptthemen laut MEDLINE: Melanoma, Mutation, Proto-Oncogene Proteins B-raf, Skin Neoplasms. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Union-Next Generation EU-NRRP M6C2-Investment 2.1 Enhancement and Strengthening of Biomedical Research in the NHS, Italian Ministry of Health, IRCCS Ospedale Policlinico San Martino, RC, Alleanza Contro il Cancro.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Non‐V600E/K BRAF mutations have been reported in melanoma, but data on their clinical relevance are conflicting. This study investigated the distribution, prognostic role, and functional impact of rare BRAF mutations in melanoma. We retrospectively assessed frequency, response to therapy and outcome of rare BRAF mutations compared to V600E/K in cases from 19 Italian Melanoma group (IMI) centers. 258/14,081 samples (1.8%) harbored rare BRAF mutations, 40% encompassing codon 600. Overall and progression‐free survival (OS, PFS) following target therapy with BRAF/MEK inhibitors were comparable to V600E/K mutant melanoma (HR = 0.85 and 0.89, p > 0.1). Response to target therapy was lower, albeit not significantly, in rare BRAF mutant melanomas compared to V600E/K (48% vs. 66%, p > 0.05). OS, PFS, and objective response in cases treated with immunotherapy were unaffected by BRAF status. Molecular dynamics simulation assessing whether selected BRAF variants affected BRAF structure similarly to V600E showed variable degrees of destabilization towards constitutive protein activation, particularly for mutations encompassing codons 599–601. These results indicate that rare BRAF mutations can modify BRAF kinase activity including a subset of mutations outside but close to codon 600. Molecular approaches able to detect rare BRAF mutations could identify additional melanoma cases eligible for therapies with BRAF/MEK inhibitors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaMutationProto-Oncogene Proteins B-rafSkin NeoplasmsHumansItalyMolecular Dynamics SimulationProtein Kinase Inhibitors

Substanzen

BRAF protein, humanProtein Kinase InhibitorsProto-Oncogene Proteins B-raf

Autor:innen und Institutionen

  • Cancer Genetics, IRCCS Azienda Ospedaliera Metropolitana, Ospedale Policlinico San Martino, Genoa, Italy.
  • Immunology and Molecular Oncology Unit, Veneto Institute of Oncology-IOV IRCCS, Padua, Italy.
  • Department of Biology, University of Padua, Padua, Italy.
  • Unit of Translational Immunology, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Melanoma Surgical Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Department of Diagnostic Innovation, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

ORCID-Profile: Laura Cendron, Ilaria Mattavelli, Andrea Carugno, Andrea Boutros, Pietro Quaglino, Paola Ghiorzo

Förderung

  • European Union-Next Generation EU-NRRP M6C2-Investment 2.1 Enhancement and Strengthening of Biomedical Research in the NHS
  • Italian Ministry of Health, IRCCS Ospedale Policlinico San Martino, RC
  • Alleanza Contro il Cancro
  • Italian Ministry of Education PRIN 2022
  • Ministero della Salute

Zitieren

APA

Dalmasso, B., Scaini, M. C., Cendron, L., Rodolfo, M., Mattavelli, I., Tamborini, E., Collina, F., Ferrara, G., Madonna, G., Cota, C., Melucci, E., Tommasi, S., Ubaldi, M., Depenni, R., Carugno, A., Marconcini, R., Orgiano, L., Lombardo, M., Sola, S., …, & Italian Melanoma Intergroup (2026). Dissecting the Spectrum of Rare BRAF Mutations in Melanoma: A Nation‐Wide Study by the Italian Melanoma Intergroup ( IMI ). Pigment Cell & Melanoma Research, 39(3). https://doi.org/10.1111/pcmr.70087

Vancouver

Dalmasso B, Scaini MC, Cendron L, Rodolfo M, Mattavelli I, Tamborini E, et al. Dissecting the Spectrum of Rare BRAF Mutations in Melanoma: A Nation‐Wide Study by the Italian Melanoma Intergroup ( IMI ). Pigment Cell & Melanoma Research. 2026;39(3). doi:10.1111/pcmr.70087

BibTeX
@article{Dalmasso2026,
  author = {Dalmasso, Bruna and Scaini, Maria Chiara and Cendron, Laura and Rodolfo, Monica and Mattavelli, Ilaria and Tamborini, Elena and Collina, Francesca and Ferrara, Gerardo and Madonna, Gabriele and Cota, Carlo and Melucci, Elisa and Tommasi, Stefania and Ubaldi, Martina and Depenni, Roberta and Carugno, Andrea and Marconcini, Riccardo and Orgiano, Laura and Lombardo, Maurizio and Sola, Simona and Pellegrini, Cristina and Castiglione, Francesca and Gasparotto, Matteo and Jorkesh, Alireza and Pellegrini, Stefania and Raposio, Edoardo and Boutros, Andrea and Tanda, Enrica Teresa and Guida, Michele and Quaglino, Pietro and Palmieri, Giuseppe and Massi, Daniela and Ascierto, Paolo Antonio and Spagnolo, Francesco and Mandalà, Mario and Menin, Chiara and Ghiorzo, Paola and Pastorino, Lorenza and Italian Melanoma Intergroup, Italian Melanoma Intergroup},
  title = {Dissecting the Spectrum of Rare BRAF Mutations in Melanoma: A Nation‐Wide Study by the Italian Melanoma Intergroup ( IMI )},
  journal = {Pigment Cell & Melanoma Research},
  year = {2026},
  volume = {39},
  number = {3},
  doi = {10.1111/pcmr.70087}
}
Kostenlos starten →